Selectivity data for probe BAY1125976 and control BAY-940
Jump to control PDSP data
BAY1125976
Compound concentration: 10 µM| Receptor | HGNC target name | Inhibition [%] (Primary experimental value) | Ki [nM] (Secondary experimental value) | pKi |
|---|---|---|---|---|
| 5-HT1B | HTR1B | 10.23 | ||
| 5-HT1D | HTR1D | 12.22 | ||
| 5-HT1A | HTR1A | 32.73 | ||
| Sigma 2 | TMEM97 | 39.93 | ||
| 5-HT2A | HTR2A | 8.08 | ||
| 5-HT2B | HTR2B | 13.39 | ||
| Alpha1A | ADRA1A | 39.41 | ||
| Alpha1B | ADRA1B | -8.97 | ||
| Alpha1D | ADRA1D | 37.75 | ||
| Beta1 | ADRB1 | 16.78 | ||
| Beta2 | ADRB2 | 21.48 | ||
| D1 | DRD1 | -3.80 | ||
| D3 | DRD3 | 22.59 | ||
| D5 | DRD5 | 23.44 | ||
| GABAA | -13.09 | |||
| H1 | HRH1 | 30.84 | ||
| H2 | HRH2 | 0.95 | ||
| H3 | HRH3 | 14.61 | ||
| H4 | HRH4 | -24.61 | ||
| M1 | CHRM1 | 71.91 | 1454.31 average (n=2) | 5.87 |
| M2 | CHRM2 | 11.18 | ||
| M3 | CHRM3 | 20.09 | ||
| M4 | CHRM4 | 12.38 | ||
| M5 | CHRM5 | 1.83 | ||
| NET | SLC6A2 | 47.47 | ||
| GABA/PBR | 40.52 | |||
| 5-HT1E | HTR1E | -13.62 | ||
| 5-HT2C | HTR2C | 25.70 | ||
| 5-HT3 | HTR3A | 10.79 | ||
| 5-HT5A | HTR5A | 9.78 | ||
| 5-HT6 | HTR6 | 17.75 | ||
| 5-HT7A | HTR7 | 12.88 | ||
| Alpha2A | ADRA2A | 6.89 | ||
| Alpha2B | ADRA2B | 28.66 | ||
| Alpha2C | ADRA2C | 38.92 | ||
| Beta3 | ADRB3 | 11.36 | ||
| GABAA/BZP | 38.00 | |||
| D2 | DRD2 | -1.55 | ||
| D4 | DRD4 | 7.35 | ||
| DAT | SLC6A3 | 40.03 | ||
| DOR | OPRD1 | 26.91 | ||
| KOR | OPRK1 | 25.42 | ||
| MOR | OPRM1 | 31.14 | ||
| SERT | SLC6A4 | 14.78 | ||
| Sigma 1 | SIGMAR1 | -1.31 |
BAY1125976
The proliferation assay was performed in 13 human breast cancer cell lines as well as 10 other cancer cell lines with alterations in PI3K/AKT/mTOR pathway components. Cell viability was determined using the CellTiter-GloVR Luminescent Cell Viability Assay (Promega). Shown are data from PMID: 27699769 (Table 1). (ER+: estrogen receptor positive; ER-: estrogen receptor negative; TN: triple-negative, i.e. does not express the genes for estrogen, progesterone receptors and ERBB2)
Conclusion: BAY1125976 inhibited the proliferation of the breast cancer cell lines BT-474, T47D, MCF7, ZR-75–1, EVSA-T, MDAMB-453, KPL-4 and BT20 as well as the prostate cancer cell lines LNCaP and LAPC-4 with submicromolar IC50 values.
| Tumor type | Cell line | Species | Cell Proliferation IC50 [µM] | Mutation status |
|---|---|---|---|---|
| Bladder cancer | KU-19-19 | Homo sapiens | 9.22 | AKT (p.E17K), NRAS (Q61R), PIK3CA (R1023Q) |
| Breast cancer (luminal, ER-) | BT-474 | Homo sapiens | 0.02 | PIK3CA (p.K111N) |
| Breast cancer (luminal, ER+) | T47D | Homo sapiens | 0.06 | PIK3CA (p.H1047R) |
| Breast cancer (luminal, ER+) | MCF7 | Homo sapiens | 0.06 | PIK3CA (p.E545K) |
| Breast cancer (luminal, ER+) | ZR-75-1 | Homo sapiens | 0.07 | PTEN (p.L108R) |
| Breast cancer (luminal, ER-) | EVSA-T | Homo sapiens | 0.12 | PTEN (p.T319fs *1) |
| Breast cancer (luminal, ER-) | MDA-MB-453 | Homo sapiens | 0.12 | PIK3CA (p.H1047R), PTEN (p.E307K) |
| Breast cancer (ER-) | KPL-4 | Homo sapiens | 0.17 | PIK3CA (p.H1047R) |
| Breast cancer (basal, TN) | BT-20 | Homo sapiens | 0.39 | PIK3CA (p.P539R) |
| Breast cancer (basal, TN) | MDA-MB-468 | Homo sapiens | 6.47 | PIK3CA (p.E545A), PTEN (p.L70fs*7) |
| Breast cancer (basal, TN) | BT-549 | Homo sapiens | 8.44 | PTEN (p.V275fs*1) |
| Breast cancer (basal, ER+) | HCC70 | Homo sapiens | 8.44 | PTEN (p.F90fs*9) |
| Breast cancer (basal, ER+) | CAL-120 | Homo sapiens | 10.00 | |
| Breast cancer (basal, TN) | MDA-MB-231 | Homo sapiens | 10.00 | BRAF (p.G464V) , KRAS (p.G13D) |
| Cervic cancer | HeLa-MaTu ADR | Homo sapiens | 0.96 | EGFR (p.I601L), PIK3CA (p.H1047R) |
| Cervic cancer | HeLa | Homo sapiens | 10.00 | |
| Colon cancer | Caco-2 | Homo sapiens | 1.56 | |
| Melanoma | B16F10 | Homo sapiens | 2.18 | |
| Melanoma | A2058 | Homo sapiens | 7.68 | BRAF (p.V600E) , PTEN (p.V175fs*3) |
| Nonsmall cell lung carcinoma | NCI-H460 | Homo sapiens | 1.54 | KRAS (p.Q61H), PIK3CA (p.E545K) |
| Prostate cancer | LAPC-4 | Homo sapiens | 0.04 | AKT (E17K), NRAS (G12D) |
| Prostate cancer | LNCaP | Homo sapiens | 0.05 | KRAS (p.G12V), PTEN (pK6fs* 4) |
| Prostate cancer | DU-145 | Homo sapiens | 3.00 | KRAS (p.G12V) |